Trials / Completed
CompletedNCT02033902
A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of Fycompa (Perampanel) as an add-on therapy in epilepsy patients aged greater than or equal to 12 years.
Detailed description
This is a global, observational, cohort study in patients with epilepsy. Multiple treating physicians will prescribe perampanel to approximately 500 patients, who then will be observed for approximately 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Perampanel | Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment |
Timeline
- Start date
- 2014-06-06
- Primary completion
- 2018-01-31
- Completion
- 2018-01-31
- First posted
- 2014-01-13
- Last updated
- 2018-09-07
Locations
42 sites across 6 countries: Austria, Belgium, Czechia, Israel, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02033902. Inclusion in this directory is not an endorsement.